Live Breaking News & Updates on Tiago Reis Marques

Stay updated with breaking news from Tiago reis marques. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated ...

Pasithea Therapeutics Announces The First Cohort Has Completed The Initial Dosing In Its Phase 1 Trial Evaluating PAS-004 In RAS, NF1 And RAF Mutated ...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Tiago Reis Marques , Pasithea Therapeutics Corp , Exchange Commission , While The Company , Chief Executive Officer , Solid Tumors , Amyotrophic Lateral Sclerosis , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United States , Tiago Reis Marques , Graeme Currie , Patrick Gaynes , While The Company , Jones Day , Corporate Communications , Pasithea Therapeutics Corp , Exchange Commission , Stereoisomer Patents , Issued Extend Portfolio , Stereoisomer Patent Filings Continue , Expand Patent Portfolio , Central Nervous System , Development Officer , Executive Officer , Solid Tumors , Amyotrophic Lateral Sclerosis , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,

Pasithea Therapeutics Announces FDA Acceptance of IND

Pasithea s IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.. ....

United States , Tiago Reis Marques , Patrick Gaynes , Corporate Communications , Us Federal Drug Administration , Pasithea Therapeutics Corp , While The Company , Exchange Commission , Central Nervous System , Investigational New Drug Application , Drug Administration , Chief Executive Officer , Eastern Europe , Solid Tumors , Amyotrophic Lateral Sclerosis , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nasdaq Ktta , Investigational New Drug , Clinical Trials , Mek Inhibitor , As 004 , Pasithea Therapeutics ,

Pasithea Therapeutics (KTTA) Announces FDA Acceptance of IND Application to Evaluate PAS-004

Pasithea Therapeutics (KTTA) Announces FDA Acceptance of IND Application to Evaluate PAS-004
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Tiago Reis Marques , Pasithea Therapeutics Corp , Us Federal Drug Administration , Pasithea Therapeutics , Central Nervous System , Investigational New Drug Application , Drug Administration , Chief Executive Officer , Eastern Europe ,

Baystreet.ca - Pasithea Jumps as FDA Grants IND Status to Cancer Treatment

Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares rise sharply first thing Tuesday. The San Francisco-based biotechnology company, focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, . ....

United States , Tiago Reis Marques , Us Federal Drug Administration , Pasithea Therapeutics Corp , Pasithea Therapeutics , San Francisco Based , Central Nervous System , Investigational New Drug Application , Drug Administration , Reis Marques , Eastern Europe ,